Key terms
About ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABUS news
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 04
10:07am ET
Arbutus Biopharma Wins Favorable Ruling Against Moderna
Apr 04
8:38am ET
Arbutus ‘pleased’ with claim construction ruling in patent infringement suit
Apr 03
3:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Apr 03
3:05pm ET
Moderna could owe $1B-$3B in royalties, says Jefferies
Apr 03
2:02pm ET
Roivant, Arbutus higher after ruling on COVID patent order
Apr 03
1:56pm ET
Jefferies sees Roivant rallying 5%-10% on today’s COVID patent order
Mar 25
4:55am ET
Arbutus Biopharma management to meet virtually with JMP Securities
Mar 20
5:20pm ET
Arbutus Biopharma management to meet virtually with JMP Securities
Mar 08
8:07am ET
Arbutus Biopharma Showcases at Investor Conferences
Mar 05
1:23am ET
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Mar 01
6:26am ET
Arbutus Biopharma price target lowered to $5 from $6 at H.C. Wainwright
Feb 29
1:55pm ET
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
Feb 29
8:19am ET
Arbutus Biopharma Anticipates Key 2024 Milestones
Feb 29
7:33am ET
Arbutus Biopharma reports FY23 EPS (44c), consensus (45c)
Feb 12
11:09am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
1:05pm ET
Jefferies ‘encouraged thus far’ by Arbutus patent hearing
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 29
4:35pm ET
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
Jan 11
6:15am ET
Optimistic Outlook for Arbutus Biopharma Amid Anticipated Positive Data and Strategic Pipeline Developments
Jan 09
8:55pm ET
Arbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospects
Jan 08
7:56am ET
Arbutus Biopharma lays out 2024 objectives, sees cash runway into Q1 of 2026
No recent press releases are available for ABUS
ABUS Financials
Key terms
Ad Feedback
ABUS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABUS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
